Kosei Maemura1, Yuko Mataki2, Hiroshi Kurahara2, Yota Kawasaki2, Satoshi Iino2, Masahiko Sakoda2, Shinichi Ueno3, Takeshi Arimura4, Ryutaro Higashi5, Takashi Yoshiura5, Hiroyuki Shinchi6, Shoji Natsugoe2. 1. Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan. Electronic address: kmaemura@m3.kufm.kagoshima-u.ac.jp. 2. Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan. 3. Clinical Oncology, Kagoshima University, Kagoshima, Japan. 4. Medipolis Proton Therapy and Research Center, Ibusuki, Japan. 5. Department of Radiology, Kagoshima University, Kagoshima, Japan. 6. Graduate School of Health Sciences, Kagoshima University, Kagoshima, Japan.
Abstract
OBJECTIVES: We compared the clinical outcomes of proton beam radiotherapy (PBRT) and those of conventional chemoradiotherapy via hyper-fractionated acceleration radiotherapy (HART) after induction chemotherapy in patients with locally advanced pancreatic cancer (LAPC). METHODS: Twenty-five consecutive patients with LAPC received induction chemotherapy comprising gemcitabine and S-1 before radiotherapy. Of these, 15 and 10 were enrolled in the HART and PBRT groups, respectively. RESULTS: Moderate hematological toxicities were observed only in the HART group, whereas two patients in the PBRT group developed duodenal ulcers. All patients underwent scheduled radiotherapy, with overall disease control rates of 93% and 80% in the HART and PBRT groups, respectively. Local progression was observed in 60% and 40% of patients in the HART and PBRT groups, respectively. However, there was no statistical significance between the two groups regarding the median time to progression (15.4 months in both) and the median overall survival (23.4 v.s. 22.3 months). CONCLUSIONS: PBRT was feasible and tolerable, and scheduled protocols could be completed with careful attention to gastrointestinal ulcers. Despite the lower incidence of local recurrence, PBRT did not yield obvious progression control and survival benefits relative to conventional chemoradiotherapy.
OBJECTIVES: We compared the clinical outcomes of proton beam radiotherapy (PBRT) and those of conventional chemoradiotherapy via hyper-fractionated acceleration radiotherapy (HART) after induction chemotherapy in patients with locally advanced pancreatic cancer (LAPC). METHODS: Twenty-five consecutive patients with LAPC received induction chemotherapy comprising gemcitabine and S-1 before radiotherapy. Of these, 15 and 10 were enrolled in the HART and PBRT groups, respectively. RESULTS: Moderate hematological toxicities were observed only in the HART group, whereas two patients in the PBRT group developed duodenal ulcers. All patients underwent scheduled radiotherapy, with overall disease control rates of 93% and 80% in the HART and PBRT groups, respectively. Local progression was observed in 60% and 40% of patients in the HART and PBRT groups, respectively. However, there was no statistical significance between the two groups regarding the median time to progression (15.4 months in both) and the median overall survival (23.4 v.s. 22.3 months). CONCLUSIONS: PBRT was feasible and tolerable, and scheduled protocols could be completed with careful attention to gastrointestinal ulcers. Despite the lower incidence of local recurrence, PBRT did not yield obvious progression control and survival benefits relative to conventional chemoradiotherapy.
Authors: Tae Hyun Kim; Woo Jin Lee; Sang Myung Woo; Eun Sang Oh; Sang Hee Youn; Hye Young Jang; Sung-Sik Han; Sang-Jae Park; Yang-Gun Suh; Sung Ho Moon; Sang Soo Kim; Dae Yong Kim Journal: Sci Rep Date: 2020-12-10 Impact factor: 4.379
Authors: Tae Hyun Kim; Woo Jin Lee; Sang Myung Woo; Hyunjung Kim; Eun Sang Oh; Ju Hee Lee; Sung-Sik Han; Sang-Jae Park; Yang-Gun Suh; Sung Ho Moon; Sang Soo Kim; Dae Yong Kim Journal: Technol Cancer Res Treat Date: 2018-01-01